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The ubiquitin proteasome system (UPS) is required for normal cell proliferation, vertebrate
development, and cancer cell transformation. The UPS consists of multiple proteins that
work in concert to target a protein for degradation via the 26S proteasome. Chains of an
8.5-kDa protein called ubiquitin are attached to substrates, thus allowing recognition by the
26S proteasome. Enzymes called ubiquitin ligases or E3s mediate speciﬁc attachment to
substrates. Although there are over 600 different ubiquitin ligases, the Skp1–Cullin–F-box
(SCF) complexes and the anaphase promoting complex/cyclosome (APC/C) are the most
studied. SCF involvement in cancer has been known for some time while APC/C’s can-
cer role has recently emerged. In this review we will discuss the importance of APC/C to
normal cell proliferation and development, underscoring its possible contribution to trans-
formation. We will also examine the hypothesis that modulating a speciﬁc interaction of
the APC/C may be therapeutically attractive in speciﬁc cancer subtypes. Finally, given that
the APC/C pathway is relatively new as a cancer target, therapeutic interventions affecting
APC/C activity may be beneﬁcial in cancers that are resistant to classical chemotherapy.
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INTRODUCTION
Any discussion of the anaphase promoting complex/cyclosome
(APC/C) pathway as a possible therapeutic target has to start
with the question of what makes APC/C unique among the many
ubiquitin ligases present in human cells. On one level APC/C is
mechanisticallysimilartotheSkp1–Cullin–F-box(SCF)ubiquitin
ligases where there are core subunits and an adaptor protein that
directly binds to a substrate. In SCFs, the four subunits are Skp1
(scaffold protein), Cul1 (scaffold protein), RING-ﬁnger compo-
nent (Rbx1), and the variable adaptor protein or F-box protein
that recognizes substrates (Zheng et al.,2002). InAPC/C there are
13 subunits as well as variable adaptor proteins termed Cdc20 (or
Fizzy; Fzy), Cdh1 (or Fizzy-related; Fzr), Cortex, Ama1, or Mfr1
Abbreviations: APC/C, anaphase promoting complex/cyclosome; bHLH, basic
helix–loop–helix; BMP, bone morphogenetic protein; Cdc20, cell division cycle
protein 20 or Fizzy, Fzy; Cdh1, Cdc20 homolog 1, or Fizzy-related, Fzr; Cdk,
cyclin-dependent kinase; CK1, casein kinase 1; D-boxes, destruction boxes; E1,
ubiquitin-activating enzyme; E2, ubiquitin-conjugating enzyme; E3, ubiquitin lig-
ases; Emi1, early mitotic inhibitor-1/Rca1; HAT, histone acetyltransferase; HDAC,
histone deacetylase; HEC1, high expression in cancer 1; Id1, inhibitor of DNA
binding 1; Id2, inhibitor of DNA binding 2, also known as inhibitor of differ-
entiation 2; JNK, c-Jun NH2-terminal kinase; MAK, male germ cell-associated
kinase; MCM, minichromosome maintenance; MEF, mouse embryonic ﬁbrob-
last; MR, methionine–arginine; NAALADase, N-acetylated alpha-linked acidic
peptidase; Nek2, NIMA-related kinase 2; NGF, nerve growth factor; OSCC, oral
squamous cell carcinomas; PC, proteasome/cyclosome; PCNA, proliferating cell
nuclear antigen; PIP3, phosphoinositide-3,4,5-triphosphate; Plk1, polo-like kinase
1; PMSA,prostate speciﬁc membrane antigen; pRb,retinoblastoma protein; preRC,
pre-replicative complex; Rbx1, RING-ﬁnger component; SCF, Skp1–Cullin–F-box;
TAME,tosyl-l-argininemethylester;TGF-β,transforminggrowthfactorbeta;TPR,
tetratricopeptide repeat; UPS, ubiquitin proteasome system.
(Acquaviva and Pines, 2006; Hutchins et al., 2010; Kops et al.,
2010). However,beyond these similarities regarding adaptors and
subunits present in APC/C and SCF ligases, large differences in
size and structure exist between these two types of ligases. By
contrast to SCF ubiquitin ligases, there is only limited knowl-
edge regarding APC/C structure mainly because the enormous
size and complexity of the holoenzyme present signiﬁcant chal-
lenges for structure determination at the atomic level. The ﬁrst
structural insights into the APC/C was obtained by cryo-EM of
complexes puriﬁed from human cells,Xenopus laevis egg extracts,
and budding yeast (Gieffers et al., 2001; Dube et al., 2005; Pass-
moreetal.,2005).3DmodelingshowedthatinallcasestheAPC/C
is an asymmetric triangular complex (200 by 230Å in size), com-
posed of an outer wall and an internal cavity. Cdh1 and the Cullin
domain of the Apc2 subunit are located on the outside of the
complex, making it plausible that ubiquitination reactions occur
on the outside and not inside the cavity. An emerging view of
the APC/C is that of a four-part enzyme composed of a struc-
tural arm or scaffolding unit made of Apc1, Apc4, and Apc5, a
catalytic arm consisting of Apc2, Apc11, and Doc1 (or Apc10),
a tetratricopeptide repeat (TPR) arm made of Cdc23, Cdc16,
and Cdc27, which mediates binding to activators and coactiva-
tors (Cdc20, Cdh1, Cortex). Other subunits such as Cdc26,Apc9,
and Swm1 stabilize the TPR arm (Schwickart et al., 2004; Thorn-
ton and Toczyski, 2006). The TPR subunits have 12–15 copies of
the 34-amino acid long TPR. They facilitate interactions between
subunits and the assembly of multisubunit complexes (Zachariae
and Nasmyth, 1999). A pseudo-atomic model of the yeast APC/C
obtained by reconstitution studies of the holoenzyme and its sub-
complexeshasrevealedthattheTPRarmalongwiththestructural
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armcoordinatethejuxtapositionof thecatalyticarmandtheTPR
phosphorylation sites relative to the coactivators, substrates, and
regulators (Schreiber et al., 2011).
A previously unidentiﬁedAPC/C subunit,Apc16,was reported
recently (Hutchins et al.,2010; Kops et al.,2010). It is a small pro-
tein of 11.7kDa in size encoded by Chromosome 10 open reading
frame 104 (C10orf104) in humans. Apc16 may facilitate Cdc27
hyperphosphorylation, although it is not essential for assembly
of the holocomplex (Kops et al., 2010). Therefore, the APC/C is
composed of multiple subunits, some of which are newly dis-
covered. However, the minimum ubiquitin ligase module of the
APC/C that can catalyze ubiquitination is comprised of just two
subunits – the Apc2 Cullin subunit and the Apc11 RING subunit
(Gmachletal.,2000;Leversonetal.,2000;Tangetal.,2001),which
are analogous to the Cullin and Rbx1 subunits of the SCF com-
plex (Barford, 2011). Thus, while we still do not have a complete
understanding of APC/C structure, we are beginning to under-
standthegeneralarchitectureof thecomplex,andpossiblyachieve
anatomiclevelresolutionofAPC/Csubcomplexes.Thesesubcom-
plexesmayprovidemultiplebindingsitesforsmallmoleculesthat
would perhaps make APC/C unique among ubiquitin ligases as a
therapeutic target.
APC/C ACTIVITY
Another attractive aspect of the APC/C as a drug target is that it
binds a unique set of enzymes required for transferring ubiqui-
tin to substrates. The process of ubiquitination begins with the
ubiquitin-activating enzyme E1 binding to and activating ubiqui-
tin in an ATP-dependent manner. This activated ubiquitin is then
transferred to a ubiquitin-conjugating enzyme or E2. The ubiq-
uitin ligases or E3 enzymes then associate with E2s to catalyze
the ubiquitin transfer to the ε-amino group of lysine residues
on substrate proteins (Ye and Rape, 2009). Multiple ubiquitin
molecules can be linked together in different ways to form polyu-
biquitin chains that satisfy different objectives. In yeast, chains
linked via Lysine 48 of ubiquitin (K48 chains) are a “proteolytic
signal” whereas those linked via Lysine 63 (K63 chains) function
as molecular scaffolds. In higher eukaryotes, the APC/C is known
tobuildatypicalK11-linkedpolyubiquitinchainsonitssubstrates
in association with its unique E2 partner, Ube2C (or UbcH10;
Wickliffe et al., 2011b). Ube2C only initiates chain formation,
however. Chain elongation is carried out by a K11-speciﬁc E2
called Ube2S (or E2–EPF) that works with both APC/CCdc20 and
APC/CCdh1 (Garnett et al., 2009; Wu et al., 2010; Wickliffe et al.,
2011a). The importance of this dual regulation of APC/C activity
via Ubch10 and Ube2S is underscored by the ﬁnding that remov-
ingK11-speciﬁcE2scausesdefectsinspindleassemblyandmitotic
progression (Williamson et al.,2009).
Oneof themostattractivemeansof attenuatingAPC/Cactivity
pharmacologicallyisbymodulatingtheadaptorprotein–substrate
binding reaction. Early studies in yeast identiﬁed the Cdc20 and
Cdh1 substrate binding adaptor proteins as required for APC/C
activity (Visintin et al., 1997). Subsequent studies in multiple
experimentalsystemsdemonstratedthebiochemicalrequirements
for these adaptors to bind their substrates (Fang et al., 1998).
Although exceptions exist, Cdc20 and Cdh1 bind substrates con-
taining the sequence elements RXXLXXXXN/D/E or destruction
boxes (D-boxes), while Cdh1 can also bind substrates contain-
ing KEN sequences (Glotzer et al., 1991; Pﬂeger and Kirschner,
2000). Substrate binding initiates ubiquitination mediated by
APC/CCdc20 or APC/CCdh1. However, APC/CCdc20 or APC/CCdh1
mediatedsubstratebindingiscontrolledduringthecellcycleusing
an overlapping series of regulatory mechanisms. Inhibitory com-
plexes control APC/C activity during the cell cycle, thus limiting
its activity to deﬁned temporal windows (for reviews see Man-
chado et al.,2010; Qiao et al.,2010; Pines,2011). One of the most
important examples of this is the exquisite control of APC/CCdc20
activity during mitosis. In early mitosis, APC/CCdc20 activity is
curtailed by the spindle assembly checkpoint (SAC), which mon-
itors the attachment of kinetochores to the mitotic spindle. An
inhibitory complex containing Mad2, Bub3, and BubR1 proteins
sequesters Cdc20 and renders it unable to bind substrates (Kim
and Yu, 2011). After the checkpoint is switched off, this com-
plex is released from APC/CCdc20, which initiates the metaphase
to anaphase transition by mediating degradation of key proteins
such as securin, shugoshin, and cyclin B1 (Kim and Yu, 2011).
SecurinandcyclinB1degradationactivatesseparase,whichcleaves
the cohesin complex that holds sister chromatids together while
shugoshin destruction relieves sister chromatid cohesion at the
centromere (Wang and Dai, 2005). These reactions are essential
for the metaphase to anaphase transition,which is inhibited when
APC/CactivityisabrogatedpharmacologicallyorbysiRNAdeple-
tionorgeneticdisruptionof Cdc20 (Huangetal.,2009;Manchado
et al., 2010; Zeng et al., 2010). Cells lacking APC/CCdc20 eventu-
ally undergo mitotic catastrophe and die in a manner reminiscent
of microtubule inhibition (Zeng et al., 2010). However, APC/C
inhibitory molecules may have the added advantage that they
will not have the usual off-target effects of microtubule inhibi-
tion well-known during chemotherapy treatment (Huang et al.,
2009; Manchado et al., 2010).
APC/CCdh1 CONTROLS SEVERAL CELL CYCLE TRANSITIONS
Small molecules that inhibit substrate ubiquitination via
APC/CCdc20 also reduce APC/CCdh1 activity (Zeng et al., 2010).
Since the APC/CCdh1 window of activity during the cell cycle
is larger than that of APC/CCdc20, it may be easier to modulate
APC/CCdh1 speciﬁc pathways necessary for growth of a partic-
ular cancer cell. APC/CCdh1 controls mitotic exit and maintains
the G1-phase in cycling cells (Figure 1). Outside the cell cycle,
APC/CCdh1 is required for quiescence, cell cycle exit, and differ-
entiation (Figure 1). These multiple roles suggest the presence of
distinct upstream regulatory and signaling pathways controlling
APC/CCdh1 within temporal or developmental windows. Impor-
tantly, these pathways will likely provide unique interactions with
APC/C that can be targeted pharmacologically.
APC/CCdh1 IS REQUIRED FOR MITOTIC EXIT AND G1 MAINTENANCE
APC/CCdh1 targets multiple substrates for degradation during
mitosis (Figure 1). Foremost among these are the mitotic cyclins,
whose degradation ablates cyclin-dependent kinase 1 (CDK1)
activity (Brandeis and Hunt, 1996; Irniger and Nasmyth, 1997).
APC/C also reduces activity of multiple CDKs by initiating degra-
dation of two components of the SCF ubiquitin ligase, the F-box
protein Skp2 and an accessory protein, Cks1 (Bashir et al., 2004;
Frontiers in Oncology | Molecular and Cellular Oncology January 2012 | Volume 1 | Article 60 | 2Penas et al. APC/C role in cancer
FIGURE 1 |APC/C
Cdh1 regulates several cell cycle phases. (1, 2)
APC/C
Cdh1promotes mitotic exit and maintains G1-phase by inhibiting CDK
activity. (3) APC/C
Cdh1 needs to be inactivated for cells to enter S phase.
APC/C
Cdh1 promotes cell cycle exit to a quiescent state (4) or differentiation
(5). APC/C
Cdh1 induces differentiation of neurons, hematopoietic cells, lens
cells, and myocytes.
Weietal.,2004).Degradationofthesetwosubstratesraisesthelev-
els of the cyclin-dependent kinase inhibitors p27Kip1 and p21Cip1,
which are normally targeted for degradation in an SCFSkp2 and
Cks1 dependent manner (Ganoth et al., 2001; Bornstein et al.,
2003). CDK inhibitors associate with speciﬁc cyclins and CDKs,
preventing them from binding to ATP, and hence blocking their
catalytic activity. Thus, high p27Kip1 and p21Cip1 levels maintain
an early G1 state by reducing CDK activity. Another mechanism
to promote G1 by reducing CDK activity involves APC/CCdh1
mediated inhibition of an activator of S phase entry, cyclin D1.
APC/CCdh1 initiates degradation of the transcription factor Ets2
(Lietal.,2008),whichnormallycontrolscyclinD1levels(Albanese
et al., 1995). Consistent with these ﬁndings, depletion of Cdh1 by
siRNA stabilizes Skp2 and Ets2, resulting in p21Cip1 and p27Kip1
degradation and cyclin D1 elevation in G1, followed by prema-
ture S phase entry (Wei et al., 2004; Li et al., 2008) and increased
proliferation (Bashir et al.,2004). Thus,APC/CCdh1 function dur-
ing mitotic exit is coupled to G1 maintenance. It initiates a sharp
decrease in CDK1 activity during mitotic exit by targeting the
mitotic cyclins for destruction and subsequently remains active
in early G1 to ensure that they remain inactive. In addition, it
ensures that other cyclin-dependent kinases,namely CDK2/cyclin
E, CDK2/cyclin A, CDK4/cyclin D, and CDK6/cyclin D are inac-
tive since it maintains high p27Kip1 levels and low cyclin D1 levels
through Skp2 and Ets2 degradation.
One question that immediately arises from these studies is that
if APC/C keeps CDKs inactive in early G1, how do cells eventu-
ally reach S phase. The answer lies in the multiple mechanisms
that decrease APC activity (Figure 1). For instance, the ubiquiti-
nation of the APC/C-speciﬁc ubiquitin-conjugating enzyme (E2)
UbcH10 by APC/CCdh1 provides a negative feedback mechanism
thateventuallydampensAPC/CCdh1 activity(RapeandKirschner,
2004; Rape et al., 2006). Further, Cdh1 is inactivated by both
phosphorylation and degradation (Lukas et al., 1999; Listovsky
et al., 2004; Benmaamar and Pagano, 2005). Finally, E2F activates
the transcription of the APC/C pseudo-substrate early mitotic
inhibitor-1 (Emi1)/Rca1 in late G1, which inhibits APC/CCdh1
activity (Hsu et al., 2002). These distinct mechanisms ensure that
APC/CCdh1 activityremainslowfromlateG1untilthesubsequent
metaphase when it is activated via reduction of CDK and Emi1
activity (Kotani et al.,1998; Hsu et al., 2002; Figure 1).
APC/CCdh1 CONTROLS PRE-REPLICATION COMPLEX FORMATION
One of the main reasons APC/CCdh1 activity must remain low
during S phase is that it is an inhibitor of pre-replication complex
formation required for S phase entry (Difﬂey, 2004). APC/CCdh1
controls the formation of the pre-replication complexes by mod-
ulating levels of three major regulators of the formation of the
complex: Orc1, Cdc6, and geminin. For DNA replication to pro-
ceed, cells need to alternate between periods of low CDK activity
and low geminin levels, in which the pre-replicative complexes
(preRCs) are assembled; and periods of high CDK activity and
high geminin levels in which origin ﬁring and DNA replication
occurs (McGarry and Kirschner, 1998; Petersen et al., 2000; Araki
et al., 2003). APC/CCdh1 is crucial to properly regulate the switch
betweenthesetwostates.Forinstance,Orc1andCdc6aredegraded
via APC/CCdh1 during early G1 (Petersen et al., 2000; Araki et al.,
2003).Further,gemininlevelsaretightlycontrolledbyAPC/CCdh1.
Geminin prohibits initiation of DNA replication at inappropri-
ate times of the cell cycle by preventing MCM recruitment at
the replication origins. During G1 the APC/C is active and as a
consequence, geminin concentration is low. At the G1–S tran-
sition, APC/C is inactivated and geminin begins to accumulate.
However, geminin concentration is not sufﬁcient to inhibit a ﬁrst
wave of preRC formation and DNA replication begins.As S phase
progresses,geminin accumulates and inhibits subsequent recruit-
mentofMCMstothereplicationorigins(McGarryandKirschner,
1998), and therefore re-duplication is avoided (McGarry and
Kirschner, 1998;Wohlschlegel et al.,2000).
APC/CCdh1 PROMOTES CELL CYCLE EXIT AND QUIESCENCE
Multiple studies suggest that a majorAPC/CCdh1 function outside
of thecellcycleislimitingCDKactivityrequiredforcellcyclepro-
gression (Qiao et al., 2010). APC/CCdh1 regulates CDK inhibitors
that reduce CDK activity and initiate cell cycle exit. Adding a
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second layer of regulation to APC/CCdh1 activity, Binné et al.
(2007) connected retinoblastoma protein (pRb) to APC/CCdh1,
Skp2, and CDK inhibitor dependent cell cycle exit. These stud-
ies demonstrated that hypophosphorylated pRb associates with
the APC/C speciﬁcally when activated by Cdh1, thus promot-
ing Skp2 degradation and accumulation of p27Kip1 and p21Cip1.
This important ﬁnding linked extracellular signaling mecha-
nisms, which normally control pRb activity to APC/C dependent
degradation of Skp2 and initiation of cell cycle exit.
Once cells have exited the cell cycle,APC/C activity is required
to maintain quiescence or differentiation. For instance, APCCdh1
inactivation by deleting its Apc2 subunit in adult hepatocytes
induced these otherwise quiescent cells to re-enter the cell cycle
(Wirth et al., 2004). Similarly, APCCdh1 has also been proposed
to block postmitotic differentiated neurons from inappropriate
cycling and apoptosis (Almeida et al.,2005; Jackson, 2006).
APC/CCdh1 REGULATES CELL CYCLE EXIT AND CELL DIFFERENTIATION
APC/CCdh1 activity promotes cell cycle exit and differentiation
since Cdh1 depletion reduces differentiation of muscle, lens,
hematopoietic,andneuronalcells(LasorellaandIavarone,2006;Li
et al.,2007;Wu et al.,2007;Garcia-Higuera et al.,2008).Although
our knowledge of the involvement of APC/CCdh1 in the differ-
entiation of other tissues awaits further investigation, its critical
function in the degradation of cell cycle proteins suggests it likely
plays relevant roles in linking quiescence and differentiation in
most cell types. Further,since cancer progression is often thought
to involve a dedifferentiation process (Daley, 2008; Trosko, 2009),
understanding APC/C’s involvement in normal cell cycle exit and
differentiation will give us clues as to how APC/C regulation or
substrate targeting may be misregulated during tumorigenesis.
Neuronal differentiation
Following a period of proliferation, neural progenitors differen-
tiate into postmitotic neurons. Since Cdh1 levels are (Gieffers
et al., 1999; Stegmuller and Bonni, 2005) higher in postmitotic
neurons relative to their neural progenitors (Yao et al., 2010),
APC/CCdh1 may play a role in neuronal cell cycle exit. Consis-
tent with this notion, an increase in APC/CCdh1 activity and a
decrease of APC/CCdh1 substrates has been observed during ter-
minal differentiation (Almeida et al., 2005; Yao et al., 2010). By
contrast,upregulationofAPC/CCdh1substrateshasbeendescribed
in human neural tumors, suggesting that APC/CCdh1 activity is
attenuated under these conditions (Lasorella and Iavarone, 2006;
Eckerle et al., 2009).
Inhibitor of DNA binding 2
One of the targets that couples APC/CCdh1 activity with neuronal
differentiation is inhibitor of DNA binding 2 (Id2, also known
as inhibitor of differentiation 2). In the developing nervous sys-
tem, Id2 has been shown to inhibit the activity of neurogenic
basic helix–loop–helix (bHLH) transcription factors required for
neuronal differentiation (Yokota, 2001; Perk et al., 2005; Roth-
schild et al., 2006; Jung et al., 2010). APC/CCdh1 targets Id2 for
destruction, which couples cell cycle exit, differentiation, and
axonalgrowthduringthedifferentiationof diverseneuronaltypes
(Lasorella and Iavarone, 2006; Yao et al., 2010). Thus, Id2 protein
downregulationviaproteolysisisessentialforneuronaldifferenti-
ation,suggestingthatderegulationofId2destructionmayunderlie
neural tumors.
Deregulated Id2 expression prevents cell cycle arrest via a wide
rangeof signals(Lasorellaetal.,2002;Kowanetzetal.,2004;Bagh-
doyanetal.,2005).Id2downregulationviadegradationallowsthe
bHLHtranscriptionfactorE47levelstoincreaseandsubsequently
promoteneuralcelldifferentiationthroughinductionof theCDK
inhibitorp57Kip2 inthedevelopingmousebrain(Rothschildetal.,
2006; Tury et al., 2011). Similarly, decreasing Id2 levels increases
expressionof knownmediatorsof neuronaldifferentiationsuchas
Hes1andAscl1(Mash1)transcriptionfactors(Havrdaetal.,2008)
and NeuroD/E47 (Jung et al., 2010). Under certain experimental
conditions, ectopic Id2 is able to drive terminally differentiated
cells back into the cell cycle (Chaudhary et al.,2005). Importantly,
theobservationthatthemostaggressivetumorsfrequentlycontain
the highest levels of Id proteins raises the possibility that deregu-
lating Id protein stability by APC/CCdh1 might also contribute to
Id accumulation in cancer.
Skp2
TheAPC/CsubstrateSkp2controlstheG1toStransitionbyelim-
inating numerous regulatory proteins that inhibit S phase entry
(Reed, 2008). The SCFSkp2 target p27Kip1 plays a large role in cell
cycle exit and differentiation, particularly neuronal differentia-
tion (Durand et al., 1998; Vernon et al., 2003; Tarui et al., 2005;
Nguyen et al., 2006, 2007). Genetic disruption of p27Kip1 causes a
general increase in cell proliferation (Fero et al., 1996; Carruthers
et al., 2003), including neurogenesis in the cortex and spinal cord
(Nguyen et al., 2007; Li et al., 2009). Control of p27Kip1 is dual,
subjecttotheaccumulationof bothcyclin-CDKcomplexes,which
promote its phosphorylation,and Skp2,which promote the ubiq-
uitination of phosphorylated p27Kip1 (Carrano et al., 1999; Mon-
tagnoli et al., 1999). Harmey et al. (2009) described an essential
roleforAPC/CCdh1 incerebellargranuleprogenitorsbymediating
Skp2 destruction, thus coordinating cell cycle exit and termi-
nal differentiation. Similar studies uncovered APC/CCdh1–Skp2
dependentdifferentiationofhumanembryonicstemcells(Bar-On
etal.,2010).Collectively,thesedatasuggestedthattwowell-known
inducers of neuronal differentiation, nerve growth factor (NGF),
and retinoic acid,hyperactivateAPC/CCdh1. NGF rapidly induced
APC/CCdh1 activityandpromoteddegradationof APCsubstrates,
including cyclin B1 and the F-box protein Skp2 (Harmey et al.,
2009). Similarly, retinoic acid promoted neuronal differentiation
through increasing APC/CCdh1 activity (Cuende et al., 2008; Yao
et al., 2010). Further, retinoic acid induced nuclear accumulation
of Cdh1,enhancingAPC/CCdh1 activity,Skp2 destabilization,and
p27Kip1 accumulation(Cuendeetal.,2008)byreducingexpression
of Rae1, a nuclear export factor that limits APC/CCdh1 activ-
ity in mitosis (Yao et al., 2010). Similar to NGF and retinoic
acid, bone morphogenetic protein 2 (BMP2) promotes cell cycle
arrest via downregulation of Skp2 and accumulation of p27Kip1
in a neuroblastoma cell line (Nakamura et al., 2003). Thus, Skp2
degradation via APC/CCdh1 is linked to neuronal differentiation
and various signaling pathways. Disruption of signaling pathways
controlling the APC/C–Skp2 axis during neuronal differentia-
tion may lead to disruption of homeostasis. Consistent with this
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possibility, reduced Skp2 and cyclin B1 expression has been seen
in a transgenic model of Down syndrome where alteration of cell
cycle rate and reduction of neurogenesis in the cerebellum was
described (Contestabile et al., 2009). Moreover, Skp2 transcript
levels gradually increase with the aggressiveness of neuroblastoma
subtype (Westermann et al.,2007),making the regulation of Skp2
by APC/CCdh1 an attractive target in tumorigenesis.
Muscle cell differentiation
Myogenesis is a multistep process that sequentially requires
the proliferation of committed myoblasts, the differentiation
of myoblasts into postmitotic myocytes, and ﬁnally fusion of
myocytestoformamultinucleatedmyotubewithcontractilecapa-
bility. In muscle, APC/CCdh1 drives cell differentiation through
the destruction of two proteins, Skp2 and Myf5 (Li et al., 2007;
Figure 1). Elimination of Skp2 leads to the accumulation of the
CDK inhibitors p21Cip1 and p27Kip1 in myoblasts, allowing cell
cycle withdrawal. Consistent with a role of p21Cip1 in myotube
formation, mice lacking p21Cip1 fail to form myotubes (Zhang
et al.,1999). Thus,the APC/C–Skp2–p21Cip1/p27Kip1 axis is likely
to be essential for muscle development.
Coupled to APC/C mediated destruction of Skp2 in muscle is
APC/C targeting of Myf5. Myf5 is a bHLH transcription factor
that regulates myoblast proliferation and homeostasis (Gayraud-
Morel et al., 2007). Its expression is restricted to dividing and
undifferentiated cells. Myf5 is not directly involved in the deci-
sion to differentiate per se but in Myf5 null animals, differentia-
tion is delayed during early regeneration and Myf5 null mutants
are characterized by a subtle progressive myopathy and muscle
regeneration deﬁcits (Gayraud-Morel et al., 2007). Degradation
of Myf5 by APC/CCdh1 facilitates myogenic fusion, a process
requiredformyoblastdifferentiation(Gayraud-Moreletal.,2007).
Importantly, impaired degradation of both Skp2 and Myf5 seems
to have a role in muscle cancer since overexpression of Skp2
and Myf5 are found in cervical carcinoma and rhabdomyosar-
comas, respectively (Tamamori-Adachi et al., 2004; Zibat et al.,
2010).
Lens cell differentiation
Proper lens differentiation requires precise temporal control of
the cell cycle and the coordination of cell cycle exit with differ-
entiation cues and signaling pathways (Zhu and Skoultchi, 2001).
APC/CCdh1 has been identiﬁed as a crucial regulator of lens dif-
ferentiation that induces SnoN degradation (Wu et al., 2007).
SnoN, a critical transcriptional corepressor of the TGF-β path-
way, has been proposed to be a functional switch controlling
the expression of p15 and p21Cip1 (Zhu et al., 2005). p21Cip1
and p15 are two essential cell cycle inhibitors that contribute to
cell cycle arrest via downregulation of cyclin D/CDK4/6 activity
(Reynisdottir et al., 1995). The upregulation of the p21Cip1 and
p15 inhibitors is necessary for coupling cell cycle withdrawal in
response to TGF-β signaling and the initiation of lens differentia-
tion. Moreover,Cdh1 depletion was shown to attenuate induction
of p15andp21Cip1 andsigniﬁcantlyblocklensdifferentiation(Wu
et al., 2007). Impaired regulation of SnoN has not been related to
corneal tumors but given the importance of APC/CCdh1 in lens
differentiation,furtherstudiescouldopennewpotentialtargetsin
these carcinomas.
Hematopoietic cell differentiation
Hematopoiesisgivesrisetoallbloodcellsthroughacomplexseries
of proliferation and differentiation events that occur through-
out lifespan (Kawamoto et al., 2010). The hematopoietic system
consists of a large array of differentiated blood cells including
erythrocytes and cells of the myeloid and lymphoid lineages. Evi-
dence supporting a role for APC/CCdh1 in hematopoiesis comes
fromCdh1knockoutmice.Cdh1heterozygousmicedevelopB-cell
lymphoma and myelodysplastic disorder (Garcia-Higuera et al.,
2008).AlthoughhowAPC/CCdh1 regulateshematopoiesisremains
to be investigated, targeted degradation of Id protein could be
one mechanism (Figure 1). While Id proteins are downregulated
during cell cycle exit, overexpression of Id proteins in terminally
differentiated cells triggers cell cycle re-entry. Id proteins mod-
ulate cellular proliferation and differentiation in hematopoietic
cells (Perk et al.,2005). Id1 is essential for hematopoietic stem cell
maintenance and hematopoietic development (Perry et al., 2007)
and the balance between Id1 and E-protein regulates myeloid-
versus-lymphoid lineage commitment (Cochrane et al., 2009).
Dysfunction of Id2 in mice or cultured cells induces lymphoid
differentiation,whereasId2overexpressioninhibitslymphoidand
myeloid differentiation (Perk et al., 2005; Ji et al., 2008). Further-
more, in addition to an Id1 and Id2 requirement for the pro-
liferation and differentiation of hematopoietic precursors, these
factors may contribute to the development of myeloid malignan-
cies through enhanced proliferation or inhibited differentiation
(Perk et al.,2005).
APC/CCdh1 PRESERVES CHROMOSOME INTEGRITY
Loss of Cdh1 function produces precocious initiation of DNA
synthesis, leading to lower S phase progression, which results
in stalled replication forks and under-replicated DNA (Garcia-
Higuera et al., 2008). These replicative defects, as well as the
upregulation of mitotic kinases, can ultimately lead to genetic
damage (Garcia-Higuera et al., 2008; Cotto-Rios et al., 2011).
Cdh1-deﬁcient cells exhibit defects in mitotic exit and cytokine-
sis and accumulate a variety of genomic aberrations (Engelbert
etal.,2008;Garcia-Higueraetal.,2008).Suchgenomicaberrations
may be a consequence of the inability of APC/CCdh1 to properly
mediate a response to DNA damage in Cdh1 null cells. In G1,
APC/CCdh1 targets the ubiquitin speciﬁc protease USP1 for pro-
teasome dependent degradation (Cotto-Rios et al., 2011). Since
USP1 counteracts monoubiquitination of the DNA repair protein
proliferating cell nuclear antigen (PCNA),APC/CCdh1 dependent
USP1 destruction allows a permissive environment during G1 for
PCNA monoubiquitination, which is required for UV-mediated
DNA gap repair (Cotto-Rios et al., 2011). In addition to USP1,
APC/CCdh1 controls the levels of multiple proteins involved in
the DNA damage checkpoint response and DNA repair includ-
ing Claspin, Rad17, thymidine kinase 1, and the ribonucleotide
reductasesubunit(Chabesetal.,2003;Keetal.,2005;Bassermann
et al., 2008; Gao et al., 2009a; Zhang et al., 2010). During G2, the
APC/CCdh1 substrate polo-kinase 1 (Plk1) controls CDK1 activa-
tion and recovery from DNA replication stresses (Watanabe et al.,
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2004;Mamely et al.,2006). Cells exposed to genotoxic stress in G2
needtoarrestthecellcycleandrepairdamagedDNA.Onemecha-
nismtoachievethisistoreducelevelsof proteinssuchasPlk1and
mitotic cyclins, which are required for mitotic entry. Although
normally inactive during G2, APC/CCdh1 is activated via Cdh1
dephosphorylation during genotoxic stress, which is mediated by
theCdc14Bphosphatase(Bassermannetal.,2008).Therefore,par-
ticipationofAPC/CCdh1 intheG2DNAdamageresponsesuggests
another mechanism for genomic instability observed inCdh1 null
cells.
APC/CCdh1 MODULATORS AS TUMOR SUPPRESSOR
PROTEINS OR ONCOGENES
Considering the prominent role of APC/C in cell cycle regula-
tion and genomic stability, it is tempting to speculate that its
dysregulation triggers a major perturbation of cell cycle progres-
sion and contributes to cell transformation. In fact, hemizygous
frameshift and point mutations in several subunits of APC/C
have been found in colon cancer cell lines and tumors (Wang
et al., 2003). Mutations in Apc3, Apc6, and Apc8 were found
in colon cancer, breast cancer, neuroblastoma, hepatocarcinoma,
melanoma,glioma,choriocarcinoma,endometrialcancer,ovarian
cancer, and prostate carcinoma (Wang et al., 2003). Overexpres-
sion studies of Apc8 suggested that APC/C mutations can act in a
dominant-negativemannertoinhibititsfunctionandcauseinap-
propriate cell cycle progression (Wang et al.,2003). Moreover,the
APC/C cofactor Cdh1 has been described as a tumor suppres-
sor (Garcia-Higuera et al., 2008). Knockdown or inhibition of
Cdh1 is associated with centrosome ampliﬁcation and chromo-
somemis-segregation,andisimplicatedingenomicinstabilityand
tumorigenesis (Ross and Cohen-Fix, 2003; Wasch and Engelbert,
2005; Engelbert et al., 2008; Garcia-Higuera et al., 2008). Cdh1-
deﬁcient mice display genomic instability and heterozygous Cdh1
micedevelopepithelialtumors,suchasmammaryglandadenocar-
cinomas and ﬁbroadenomas,which are not observed in wild-type
mice. Furthermore, these tumors contain one Cdh1 wild-type
allele, suggesting that Cdh1 is haploinsufﬁcient for tumor sup-
pression. In addition to mutations in APC/C or Cdh1 subunits,
it is tempting to speculate that alterations of APC/C upstream
regulators may lead to transformation (Table 1).
RETINOBLASTOMA PROTEIN
A well-established tumor suppressor protein that positively regu-
latesAPC/CactivityisthepRB.pRBplaysmultiplerolesduringthe
cell cycle; it blocks cell cycle progression from G1 to S phase, and
guardsthecellfromreplicatingdamagedDNA,thuspreventingthe
integration of mutations into the genome. This tumor suppressor
function requires binding and repressing the E2F family tran-
scription factors (Classon and Harlow, 2002; Chen et al., 2009).
ReversionofthepRb–E2Finteractionoccursaftermitogenicstim-
uli sufﬁcient for the activation of CDKs that phosphorylate pRB
in the nucleus. Subsequently,phospho-pRb is released from E2Fs,
whichcantheninduceSphaseentry(Thomaetal.,2011).Consis-
tent with a direct inhibitory role in S phase entry, loss of various
pRBsleadstounscheduledcellproliferationinmanytissues(Vidal
and Koff, 2000; Cobrinik, 2005; Marx et al., 2010). Accordingly,
mutations in Rb are found in a wide variety of cancers mainly
in the lung, breast, and eye (Meraldi et al., 1999; Sabado Alvarez,
2008).
Retinoblastoma protein also possesses E2F-independent func-
tions that contribute to cell cycle control. pRB interacts with both
Skp2 (Ji et al., 2004) and with APC/CCdh1 through distinct sur-
faces(Binnéetal.,2007).pRBneedstointeractwithbothproteins
to target Skp2 for ubiquitin-mediated degradation and promote
p27Kip1 accumulation and cell cycle exit. Interestingly, similar to
E2F1, Cdh1 only interacts with the hypophosphorylated (active)
form of pRb, and phosphorylation of pRb by cyclin A/CDK2
kinase abolished the ability of Rb to interact with both Cdh1
and E2F1. Therefore Cdh1, by competing with pRb interaction,
can also regulate the activity of the E2F1 transcription factor
(Sorensen et al., 2000; Gao et al., 2009a). Further, given that both
pRB and Cdh1 have tumor suppressive functions, whether the
pRB–APC/CCdh1interactionismisregulatedduringtumorigenesis
should be investigated (Figure 2).
PTEN
Recent studies have demonstrated that the well-characterized
tumor suppressor protein PTEN is a positive regulator of APC/C
activity.PTEN(Cairnsetal.,1997;Stecketal.,1997;Feilotteretal.,
1998; Gray et al., 1998; Li and Sun, 1998) encodes a lipid phos-
phatase,which plays a crucial role in adhesion,migration,growth,
and apoptosis. Pten-null mice die embryonically, but heterozy-
gous mice survive and develop tumors in the lymphoid system,
endometrium,prostate,andthethyroid(DiCristofanoetal.,1998;
Podsypanina et al.,1999). Pten somatic mutations occur in a large
percentage of human cancers, with the highest numbers found in
endometrial, central nervous system, skin, and prostate cancers
(Chalhoub and Baker, 2009).
The effects observed after PTEN loss have been attributed to
activation of the PI3K/AKT pathway as PTEN can dephosphory-
late phosphoinositide-3,4,5-triphosphate (PIP3), a potent activa-
tor of Akt1 (Maehama and Dixon, 1998). PTEN inactivation by
phosphorylation or oxidation in human cancer results in elevated
Akt1 activity and abnormal growth regulation (Silva et al., 2008;
ChalhoubandBaker,2009;McCubreyetal.,2011).However,func-
tions independent of its phosphatase activity have been described
(Maier et al., 1999; Georgescu et al., 2000; Koul et al., 2002a,b;
Gildea et al., 2004; Blanco-Aparicio et al., 2007). Recently, a novel
interaction between PTEN and APC/CCdh1 has been reported
(Song et al., 2011). Song et al. (2011) demonstrated that nuclear
PTEN directly enhances the activity of APC/C by promoting its
association with Cdh1 in a phosphatase-independent manner.
Conversely,PTENlossimpairstheactivityof theAPC/CCdh1 com-
plex.Therefore,lossofPTENfunctiondecreasesAPC/CCdh1 activ-
ity, suggesting novel molecular pathways that may be involved in
theprogressionandinitiationof tumorigenesis.Thisinturnhigh-
lights the complexity of the dose-dependent tumor promoting
and fail-safe cellular responses evoked by PTEN loss. Accordingly,
tumor-derivedmutationsthatdonotaffectthephosphataseenzy-
matic activity of PTEN in vitro have also been identiﬁed. These
were found to affect the compartmentalization of PTEN in the
cell, either by sequestering PTEN in the nucleus (Denning et al.,
2007) or by interfering with PTEN’s recruitment to the plasma
membrane (Lee et al., 1999; Georgescu et al., 2000; Walker et al.,
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Table 1 | Modulators ofAPC/CCdh1 dysregulated in cancer.
APC/C
regulator
Effects onAPC/C Major cell
cycle function (s)
Role in tumorigenesis Relevant cancers Relevant reference
PTEN Activator. Promotes the
interaction between
APC/C and Cdh1
Promotes cell
differentiation.
Downregulation
promotes cell
proliferation
Acts as a tumor
suppressor. Null mice die
and heterozygous develop
tumors
Lymphoid system,
endometrium, thyroids,
central nervous system,
skin, prostate, breast
Chalhoub et al. (2009),
Hollander et al. (2011),
Song et al. (2011), Uddin
et al. (2004), Kwon et al.
(2008)
pRB Activator. Promotes
degradation of Skp2 by
interaction with APC/C
and Skp2
Blocks progression of
G1/S. Downregulation
promotes cell
proliferation
Acts as a tumor
suppressor. Prevents
integration of DNA damage
Lung, breast, eye Chen et al. (2009), Clas-
son and Harlow (2002),
Ji et al. (2004), Binné
et al. (2007), Sabado
Alvarez (2008)
Sirt2 Activator. Acetylates
Cdh1 and Cdc20
promoting their
interaction with APC/C
Regulates
chromosomal
condensation during
mitosis. Maintains
genome integrity
Acts as a tumor
suppressor. Decrease of
function promotes
genome instability
Breast, liver, brain,
kidney, and prostate
cancers
North andVerdin (2007),
Kim et al. (2011)
PSMA Activator. Associates
with Cdc27
Unknown Acts as an oncogene.
Overexpression promotes
premature activation of
APC/C and aneuploidy
Prostate cancer Rajasekaran et al.
(2005, 2008), Burger
et al. (2002), Chang
et al. (1999, 2001)
Emi1 Inhibitor. Binds to
APC/C
Permits accumulation
of cyclins in G1/S
Overexpression with p53
knock down promotes
proliferation and
chromosomal instability
Kidney, liver, lung,
endometrium, lymphoid
system, ovarium, lung
Hsu et al. (2002), Miller
et al. (2006), Lehman
et al. (2006), Gütge-
mann et al. (2008)
MAK Inhibitor.
Phosphorylates Cdh1
Promotes stabilization
of APC/CCdh1
substrates
Acts as an oncogene.
Overexpression promotes
extra-centrosomes
Prostate cancer Wang and Kung (2011)
FIGURE 2 | Dysregulation ofAPC/C
Cdh1 modulators can promote cancer.
Decreasing expression of the tumor suppressors pRB, PTEN, and Sirt2 may
promote APC/C
Cdh1 inactivation, leading to cell proliferation and tumorigenesis.
pRB downregulation may decrease Skp2 destruction. Decreasing PTEN levels
might reduce APC/C activity. Decrease of Sirt2 could enhance the acetylation
of the coactivators Cdh1 and Cdc20, lowering the capacity to interact with
APC/C. In addition to the tumor suppressors, the oncogenes Emi1, PSMA,
and MAK also regulate APC/C
Cdh1 activity. Emi1 binds as a pseudo-substrate
and leads to APC/C inactivation. PSMA and MAK increase APC/C
Cdh1 activity
and produce genomic instability.
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2004), thus possibly negatively impacting the PTEN–APC/CCdh1
interaction.Consistentwiththispossibility,APC/CCdh1 substrates
are overexpressed in tumors containing PTEN deﬁciency (Marino
etal.,2002;Gaoetal.,2009a;Liuetal.,2011b).Further,PTENover-
expression has been found to suppress tumorigenesis by inducing
G1cellcyclearrestinhumanglioblastomacells(LiandSun,1998).
Given the importance of PTEN and APC/CCdh1 for cancer pro-
gression,itwillbecrucialtodeterminewhethertumorscontaining
PTENmisregulationhavebothhyeractivationoftheAkt1pathway
and dysregulation of APC/CCdh1 function (Figure 2).
EARLY MITOTIC INHIBITOR-1
The Emi1 is an APC/C inhibitor, which is overexpressed in mul-
tiple tumors. Emi1 is a key cell cycle regulator that is required
for accumulation of mitotic cyclins and other critical cell cycle
regulators during S phase and G2 (Hsu et al., 2002). At the G1/S
transition, Emi1 functions as a pseudo-substrate inhibitor of the
APC/C (Miller et al., 2006), allowing substrates to accumulate
(Guardavaccaro et al., 2003; Miller et al., 2006). In early mito-
sis, Emi1 is phosphorylated by Plk1 (Hansen et al., 2004), which
triggersSCFβTrCP-dependentubiquitinationanddestruction,thus
inducing APC/C activation and mitotic progression (Margottin-
Goguet et al., 2003). Emi1 overexpression leads to unscheduled
cellproliferation,tetraploidy,andchromosomalinstabilityinp53-
deﬁcient cells (Lehman et al., 2006; Figure 2). In p53 wild-type
cells, the induction of tetraploidy and aneuploidy by overex-
pressing APC/C inhibitors like Emi1 typically leads to G1 arrest
or apoptosis. Indeed, Emi1 overexpression causes mitotic cata-
strophe and genomic instability through APC/C misregulation,
and thus potentially contributes to tumorigenesis (Hsu et al.,
2002). Upregulation of Emi1 mRNA has been found in a variety
of malignant tumors compared to matched normal and benign
tumor tissue. Notably, Emi1 protein is highly expressed in renal
cell carcinomas, cervical adenocarcinomas, hepatocellular car-
cinomas, oligodendrogliomas, lung adenocarcinomas, endome-
trial cancers, of melanomas, many lymphomas and ovarian clear
cell carcinoma (Lehman et al., 2006; Gütgemann et al., 2008).
Emi1 expression is also related to the pRB/E2F pathway since
Emi1 is a target of the E2F transcription factor. At the G1-S
transition Emi1 is transcriptionally induced by E2F, thus accel-
erating S phase entry (Hsu et al., 2002). The importance of
this regulation is underscored by the ﬁnding that lack of pRb
repression of E2F-mediated transcription causes misregulation of
Emi1 and APC/C substrates in malignant tumors (Lehman et al.,
2006).
Sirt2
Recently, the histone deacetylase (HDAC) SIRT2 has been shown
to positively regulate APC/C activity (Kim et al., 2011). Histone
acetyltransferases (HATs) and HDACs are enzymes controlling
protein acetylation. Both target histones, whereas HATs catalyze
the acetylation of histones and relax chromatin to increase acces-
sibility of transcription factors to promoters of target genes,
HDACsremoveacetylgroupsfromhistonesandrepresstranscrip-
tion (Strahl and Allis, 2000). Most of them have been found in
transcription factor complexes and, therefore, have been consid-
ered to regulate transcription by modulating acetylation levels of
chromatin (Kuo and Allis, 1998; Kouzarides, 1999). HDACs are
important for cell cycle progression and their inhibition promote
cell arrest in G1 and G2 (Marks et al., 2001; Johnstone and Licht,
2003; Noh and Lee, 2003). HDACs also have an important role in
heterochromatin formation and maintenance (Olsson et al.,1999;
Taddeietal.,2001)andareimplicatedinchromosomesegregation
(Nakayamaetal.,2003;Silversteinetal.,2003;Kimataetal.,2008).
Several HDACs have a role in tumorigenesis, acting as a sup-
pressors or promoters (Lagger et al., 2002; Glaser et al., 2003;
Saunders and Verdin, 2007; Wang et al., 2008a,b; Deng, 2009; Bell
et al., 2011; Kim et al., 2011) and HDAC inhibitors are a promis-
ingclassof anti-canceragents(JohnstoneandLicht,2003;Yoshida
et al.,2003; Bolden et al.,2006). SIRT2 is predominantly localized
in the cytoplasm where it deacetylates microtubules (North et al.,
2003). During mitosis, SIRT2 is localized to chromosomes reg-
ulating chromosomal condensation (Vaquero et al., 2006; Inoue
et al.,2007),and is also associated with mitotic structures,includ-
ing the centrosome, mitotic spindle, and midbody, presumably
to ensure normal cell division (North and Verdin, 2007). Kim
et al. (2011) demonstrated that SIRT2 regulates APC/C activ-
ity through deacetylation of its coactivators Cdh1 and Cdc20.
Deacetylation of Cdh1 and Cdc20 by SIRT2 enhances the inter-
action of these coactivators with Cdc27, leading to activation of
APC/C. In Sirt2 mutant mice, reduced APC/C activity results
in tumor formation by producing genomic instability associ-
atedwithcentrosomeampliﬁcation,aneuploidymitoticcelldeath,
and spontaneous tumor formation. These deﬁciencies seem to be
caused by a combined effect of altered expression of mitotic regu-
latorsthatarecontrolledbyAPC/C(Figure2).Accordingly,SIRT2
expression is reduced in several human malignancies includ-
ing breast, liver, brain, kidney, and prostate cancers (Kim et al.,
2011).
PSMA AND MAK
Mitoticdefectsassociatedwithchromosomalaberrationsareoften
observed in prostate cancer cells and tissue, suggesting possible
misregulation by APC/C (Tribukait, 1991; Beheshti et al., 2001;
Pihan et al., 2001). Two regulators of the APC/C have been
found to be clearly involved in prostate cancer, prostate spe-
ciﬁc membrane antigen (PMSA) and male germ cell-associated
kinase (MAK). PSMA is a type II transmembrane protein that
exhibits both N-acetylated alpha-linked acidic peptidase (NAAL-
ADase) and folate hydrolase activities (Ghosh and Heston, 2004;
Rajasekaran et al., 2005). PSMA is localized to secretory cells
within the prostatic epithelium although its physiological and
pathological functions remain unclear. PSMA is upregulated in
advanced prostate carcinoma and metastatic disease (Rajasekaran
et al., 2005), and is a feature of practically every prostatic tissue
examined(Rajasekaranetal.,2005,2008).PSMAisabsentormod-
erately expressed in hyperplastic and benign tissues, while malig-
nanttissueshavehighlevels,demonstratingthatPSMAexpression
increases proportionally to tumor aggressiveness (Troyer et al.,
1995; Kawakami and Nakayama, 1997; Liu et al., 1997; Silver
et al., 1997; Sweat et al., 1998; Chang et al., 1999, 2001; Burger
et al., 2002; Ross et al., 2003). PSMA is localized to a mem-
brane compartment in the vicinity of centrosomes at the spindle
poles and associates with the APC/C subunit Cdc27 leading to
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premature activation of APC/C, and induction of aneuploidy
(Rajasekaran et al., 2008). Increased APC/C activity observed
in PSMA expressing cells is sufﬁcient to impair the mitotic
spindle checkpoint, which agrees with the ﬁnding that PSMA
expressing cells exit mitosis prematurely (Figure 2). Therefore,
PSMA may have a causal role in the progression of prostate
cancer.
Male germ cell-associated kinase belongs to a protein kinase
family characterized by a catalytic domain resembling a hybrid
of the TXY motif found in mitogen-activated protein kinases
(MAPK) and the TY motif in CDKs (Payne et al., 1991; Brown
et al., 1999; Xia et al., 2002; Fu et al., 2005). MAK expression
is elevated in castration-resistant prostate cancer cell lines and
is generally overexpressed in prostate tumors, thus possibly con-
tributing to malignancy via aberrant regulation of mitosis (Wang
and Kung, 2011). MAK protein has a dynamic subcellular local-
ization during the cell cycle: it is localized to the mitotic spindle
and centrosomes during metaphase and anaphase, and to the
mitotic midbody from anaphase to telophase. MAK negatively
regulates APC/CCdh1 through interaction and phosphorylation
of Cdh1 in CDK phosphorylated sites, in a manner reminis-
cent of CDK-dependent inactivation of Cdh1 (Wang and Kung,
2011; Figure 2). The phosphorylation of MAK increases between
S and G2, peaks at early mitosis, and drastically decreases at
the end of mitosis. This promotes the dissociation of Cdh1 and
APC/C thus decreasing APC/CCdh1 activity and promoting the
stabilization of the substrates Aurora kinase A and Plk1. As over-
expression of Aurora-A is known to induce centrosome ampli-
ﬁcation (Zhou et al., 1998), the extra-centrosomes observed in
MAK overexpressed cells is likely due to cellular accumulation of
Aurora-A.
APC/C SUBSTRATES IN CANCER
Many APC/C substrates have been implicated in a variety of
human cancers (Table 2). For those substrates that are over-
expressed in cancer it is important to note that overexpression
of an APC/C substrate inﬂuences degradation of other APC/C
substrates (Rape and Kirschner,2004),suggesting that global esti-
matesofAPC/Csubstratelevelsarerequiredinnormalanddisease
states. Further, while there are arguably many APC/C substrates
that may be important for cancer progression, classifying their
relative importance and druggability is essential.
NIMA-RELATED KINASE 2
TheproteolysisofAPC/Csubstratesstartsascellsmakethetransi-
tion from G2 to M phase. One of the earliest targets is the NIMA-
relatedkinase2(Nek2)familyof serine/threonineproteinkinases.
They are implicated in the regulation of centrosome separation
and spindle formation. Nek2A, along with cyclin A are unique
APC/CCdc20 substrates that get degraded during prometaphase
even when the SAC is active.A C-terminal dipeptide methionine–
arginine (MR) tail enables Nek2A to directly bind the APC/C
independentlyofCdc20(Hayesetal.,2006).Nek2levelsareupreg-
ulated in human breast cancer,pediatric osteosarcoma,and B-cell
lymphomas (Wai et al., 2002; de Vos et al., 2003; Hayward et al.,
2004).
CELL DIVISION CYCLE PROTEIN 20
Cell division cycle protein 20 is an essential coactivator of the
APC/C during mitosis. Multiple studies have indicated that main-
taining appropriate Cdc20 levels is important for cellular home-
ostasis. When this is disturbed and Cdc20 is overexpressed,
tumorigenesis can occur. For instance, oral squamous cell carci-
nomas (OSCC) and breast cancer cells overexpress Cdc20 causing
premature anaphase and aneuploidy linked to tumor formation
(Yuanetal.,2006;Mondaletal.,2007).Importantly,evenatwofold
overexpression of Cdc20 leads to spindle checkpoint defects and
early Pds1 (securin) destruction producing aneuploidy (Pan and
Chen, 2004).
One of the major ways Cdc20 protein levels are controlled is
via the SAC.When the SAC is active during metaphase,the check-
pointproteinsMad2,BubR1,andBub3bindtoCdc20andconvert
it into a substrate of APC/CCdc20. This allows for the ubiquitina-
tionanddegradationofCdc20byAPC/CCdc20 (Nilssonetal.,2008;
Ge et al., 2009). Thus, SAC activation inhibits Cdc20 and arrests
cells in metaphase. Inactivation of SAC at the end of metaphase
relievesthisinhibitionandCdc20promotesmitoticexitbydegrad-
ing key substrates such as the mitotic cyclins. The importance of
SACdependentcontrolof Cdc20levelsisunderscoredbytheﬁnd-
ing that anti-mitotic cancer drugs that activate the SAC cause cell
cycle arrest. These drugs cause a prolonged metaphase arrest that
may eventually lead to cell death. However,during this prolonged
metaphase arrest, some Cdc20 escapes inhibition by the SAC and
asaresult,cyclinB1levelsstarttofallandcellsexitmitosis,thereby
initiating mitotic slippage (Nilsson, 2011). This may be especially
true in some cancer subtypes since the frequency of mitotic slip-
pageishastenedintumorcellslackingp53andpRb(Depamphilis,
2011). Further, mitotic slippage reduces the sensitivity of tumor
cells to chemotherapeutics. Thus, alternative means of inhibiting
Cdc20 are needed.
Recent evidence suggests that targeting Cdc20 directly could
be a better alternative than targeting the SAC in cancer therapy
(Huangetal.,2009;Manchadoetal.,2010). Knockdown of Cdc20
by siRNA induces mitotic arrest and apoptosis in various cancer
cell lines that are otherwise resistant to apoptosis and prone to
mitotic slippage (Huang et al., 2009). Further, genetic ablation of
theCdc20 geneinmurineskintumorandaggressiveﬁbrosarcoma
models results in complete tumor regression (Manchado et al.,
2010). Cdc20 deletion induces metaphase arrest and apoptosis in
tumor cells both in vitro and in vivo. Importantly, the activities
of Cdk1 and Mast1 kinases are required for this arrest. When
Cdk1andMast1kinasesareinhibited,Cdc20 nullcellsexitmitosis
via the activities of the phosphatases PP2A/B55α and PP2A/B55δ
(Manchadoetal.,2010).Thus,smallmoleculesattenuatingCdc20
coupled with those inhibiting these phosphatases may be effective
therapeutically.
GEMININ
Another APC/C substrate degraded at the metaphase–anaphase
transitionisgeminin.Itisasmall25kDaproteinthatinhibitsDNA
re-replication during S phase. Geminin levels accumulate during
S, G2, and early mitosis. It suppresses the DNA replication factor
CDT1 that is required for the formation of preRCs. Depletion of
geminin by siRNA in tumor cells leads to DNA re-replication,cell
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cycle arrest,and apoptosis. However,regulation of CDT1 by gem-
inin is found to be rate limiting for initiation of DNA replication
only in cancer cells and not in normal or immortalized cells. Nor-
mal cells show the same effect only when cyclin A is co-depleted
withgeminin(ZhuandDepamphilis,2009).Thusithasbeenpro-
posedthatinhibitionof gemininactivitycanbeusedtoselectively
kill cancer cells (Zhu and Depamphilis, 2009).
POLO-LIKE KINASE 1
Toward the end of anaphase, the pro-mitotic regulatory kinase
Plk1, is degraded by APC/CCdh1 in a D-box dependent manner
(Lindon and Pines, 2004). Plk1 is a major kinase in eukary-
otic cells involved in a variety of processes such as activation of
the maturation promoting factor (MPF) by phosphorylation of
Cdc25C and cyclin B1, bipolar spindle formation, and matura-
tion of the centrosome (Ohkura et al.,1995; Lane and Nigg,1996;
Abrieu et al.,1998;Qian et al.,1998;Eckerdt et al.,2005). Elevated
Plk1 levels are present in a broad spectrum of cancers includ-
ing breast cancer, colorectal cancer, ovarian cancer, melanomas,
pancreatic cancer,prostate cancer,lung cancer,and squamous cell
carcinomas of the head and neck (Wolf et al., 1997, 2000; Knecht
et al., 1999; Strebhardt et al., 2000; Macmillan et al., 2001; Gray
et al., 2004; Weichert et al., 2004). This broad range of expres-
sion makes Plk1 a prime target in cancer (Strebhardt and Ullrich,
2006).
AURORA-A
Another APC/CCdh1 substrate during late mitosis is Aurora-A
(STK15/BTAK), a serine/threonine kinase localized to the cen-
trosome controlling mitotic spindle assembly and centrosome
maturation. It is involved in a variety of human cancers (Bischoff
et al., 1998; Zhou et al., 1998; Sen et al., 2002; Mondal et al.,
2007).EctopicexpressionofAurora-Aleadstochromosomeinsta-
bility and centrosome ampliﬁcation (Miyoshi et al., 2001). One
way it achieves this is by phosphorylating and regulating Centrin,
the calcium-binding phosphoprotein located in the centrosome.
Phosphorylated Centrin is more stable against APC/CCdh1 medi-
ated destruction and an excess of it is thought to promote centro-
some ampliﬁcation in cancer (Lukasiewicz et al.,2011). Aurora-A
itself becomesresistanttoAPC/CCdh1 mediateddegradationwhen
itisconstitutivelyphosphorylatedonSer51,andconsequentlygets
overexpressed in head and neck cancers (Kitajima et al.,2007).
HIGH EXPRESSION IN CANCER 1
High expression in cancer 1 (HEC1), a recently identiﬁed
APC/CCdh1 substrate, is part of the NDC80 complex controlling
kinetochoremicrotubuledynamics.HEC1levelspeakduringearly
mitosisandfallbytelophase(LipkowitzandWeissman,2011).The
mitotic regulatory kinase Nek2 phosphorylates HEC1 on Ser 165
thus activating it during G2/M. Inactivation of HEC1 results in
severe chromosome segregation defects (Chen et al., 1997, 2002;
Zheng et al.,1999). HEC1 is considered as a candidate marker for
breastlesionslikelytoundergomalignanttransformationbecause
it is signiﬁcantly overexpressed in benign breast tumors (Bieche
et al.,2011). A small molecule called INH1,which binds to HEC1
and speciﬁcally disrupts the HEC1–Nek2 interaction, is found to
suppress human breast cancer cell proliferation in culture as well
astumorgrowthinnudemicebearingxenografts(Wuetal.,2008).
c-Jun NH2-TERMINAL KINASE
c-JunNH2-terminalkinase(JNKs),aclassof MAPK,leadthecell’s
response to stress stimuli such as heat shock, radiation, and cyto-
toxic and genotoxic stress. Recently, nuclear JNK was found to be
a substrate of APC/CCdh1 during late mitosis and G1 (Gutierrez
et al.,2010a). JNK,in turn,controls APC/CCdh1 by phosphorylat-
ingCdh1atthreeresidues(Yuetal.,1998;Summersetal.,2008)to
prevent premature Cdh1 association with the APC/C during G2.
JNK-induced phosphorylation of key regulators not only controls
cell survival and differentiation, but also cell cycle progression.
JNK phosphorylates Cdc25C at Ser 168 in G2, downregulating
its phosphatase activity required for CDK1 activation (Gutierrez
et al., 2010b). This is required for the correct timing of mitotic
entry and the proper establishment of G2/M checkpoint upon
UV irradiation. However, constitutively active JNK causes defects
in cell cycle progression. Indeed, many human tumors have been
reported to require JNK activity for their growth and survival
(Potapova et al., 2000; Antonyak et al., 2002; Tsuiki et al., 2003;
Yangetal.,2003;Lopez-Bergamietal.,2007;Alexakietal.,2008).In
gastrointestinal cancers, a small molecule inhibitor of JNK shows
promise as a therapeutic agent, because it induces cell cycle arrest
and apoptosis (Xia et al., 2006).
Ect2
TheoncogenicproteinEct2isubiquitinatedbyAPC/CCdh1 shortly
after completion of mitosis (Liot et al., 2011). Ect2 is a posi-
tive regulator of the Rho GTPase pathway that controls cell cycle
progression and cytokinesis (Bustelo et al., 2007). Many human
tumors overexpress Ect2 (Sano et al., 2006; Salhia et al., 2008;
Justilien and Fields, 2009; Justilien et al., 2011). Until now, this
overexpression was believed to be a result of gene ampliﬁcation
and transcriptional upregulation (Seguin et al., 2009; Liot et al.,
2011).ButthenewlydiscoveredAPC/CCdh1 dependentproteolysis
of Ect2 shows that impaired destruction can also be a reason for
increased Ect2 levels in tumor cells,which possibly asserts the role
of Cdh1 as a tumor suppressor protein.
Skp2
Skp2 is one of the most important substrates targeted by
APC/CCdh1 during mitotic exit. An SCF containing Skp2 targets
the essential cell cycle substrates p27Kip1,p21Cip1, and FOXO1 for
degradation (Yu et al., 1998; Tsvetkov et al., 1999; Huang et al.,
2005). Destruction of the CDK inhibitor p27Kip1 is a prerequisite
for entry into mitosis. Once cells exit mitosis, APC/CCdh1 targets
Skp2 for proteolysis in G1 (Bashir et al., 2004; Wei et al., 2004).
Skp2 functions as an oncogene because most of its ubiquitina-
tiontargetsaretumorsuppressorproteins.Thusoverexpressionof
Skp2iscommoninmanycancersincludingbreastcancer,prostate
cancer, pancreatic cancer, hepatocellular carcinomas, melanomas,
and malignant lymphomas (Lim et al., 2002; Yang et al., 2002;
Radke et al., 2005; Lu et al., 2009; Rose et al., 2011; Schuler et al.,
2011). Importantly, the Akt1 serine/threonine kinase phospho-
rylates Skp2 at Ser 72 promoting its cytoplasmic translocation
and impairing degradation by APC/CCdh1 (Gao et al., 2009b,c;
Lin et al., 2009). Since the Akt1 pathway is also found to be
hyperactive in cancer cells,it may contribute signiﬁcantly to over-
expression of Skp2 protein found in some cancers (Gao et al.,
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2009b,c). Opposing the Akt1 pathway is PTEN, which is fre-
quentlymisregulatedinhumanbrain,breast,prostatecancers,and
leukemias(Lietal.,1997;Dahiaetal.,1999).Thus,PTENmisregu-
lationmaycontributetoAkt1hyperactivationandincreasedlevels
of Skp2 in tumors.
Ube2C (UbcH10)
Ube2C is an E2 enzyme that works exclusively with the APC/C
throughout the cell cycle. However, Ube2C levels peak during
mitosis and fall as cells enter G1, ﬁnally becoming a substrate for
APC/CCdh1 at the end of G1 (Rape and Kirschner,2004;Summers
et al., 2008). When Ube2C is overexpressed in mouse embry-
onicﬁbroblasts(MEFs),precociouscyclinB1degradation,mitotic
slippage,andchromosomeabnormalitieshavebeenobserved(van
Ree et al., 2010). Importantly, elevated Ube2C levels is a com-
mon feature in a wide variety of human cancers including lung,
prostate, breast, bladder, ovarian, uterine, thyroid, esophageal,
and gastric carcinomas (Okamoto et al., 2003; Pallante et al.,
2005; Berlingieri et al., 2007; Jiang et al., 2008; van Ree et al.,
2010). Further, induced expression of high levels of Ube2C
hastens tumor formation in transgenic mice (van Ree et al.,
2010).
MODULATING APC/CCdh1 ACTIVITY IN CANCER
TARGETING APC/CCdh1SUBSTRATES
Several APC/C substrates are overexpressed in various can-
cers, making them prime targets for small molecule inhibition
(Table 2). One potential APC/C substrate that could be targeted
Table 2 | Substrates ofAPC/C overexpressed in cancer.
APC/C substrate Major cell cycle function(s) Role in tumorigenesis Relevant cancers Relevant reference
Nek2 Regulation of centrosome
separation and spindle
formation
Formation of multinucleated
cells with supernumerary
centrosomes
Cervical cancer, B-cell
lymphoma, pediatric
osteosarcoma, breast cancer,
leukemia, ovarian cancer
Wai et al. (2002), de Vos et al.
(2003), Hayward et al. (2004)
Cdc20 Essential APC/C coactivator in
early mitosis
Spindle checkpoint defects
and premature Securin
destruction leading to mitotic
slippage
Oral squamous cell
carcinomas, breast cancer
Yuan et al. (2006), Mondal et al.
(2007)
Plk1 Activation of MPF by
phosphorylation of Cdc25C
and Cyclin B Assembling the
mitotic spindle
Overexpression in cancer
drives cells into mitosis
Lung, ovarian, breast, colon,
prostate and pancreatic
cancers, head/neck squamous
cell carcinomas, melanomas
Wolf et al. (1997), Knecht et al.
(1999), Strebhardt et al. (2000),
Wolf et al. (2000), Macmillan
et al. (2001), Gray et al. (2004),
Weichert et al. (2004)
Aurora-A Controls centrosome
maturation and mitotic
spindle formation
Induces centrosome
ampliﬁcation and aneuploidy
by hindering APC/CCdh1
mediated destruction of
Centrin
Bladder, lung, and colon
cancers
Bischoff et al. (1998), Zhou et al.
(1998), Sen et al. (2002), Gu et al.
(2007)
HEC1 Controls kinetochore
microtubule dynamics as part
of the NDC80 complex
Chromosome
mis-segregation
Breast cancer Bieche et al. (2011)
JNK Central role in stress
response pathways Ensures
correct timing of mitotic entry
by phosphorylating Cdc25C
Supports survival of tumor
cells by controlling cell cycle
arrest and apoptosis
Brain tumors such as
glioblastoma, prostate cancer,
gastrointestinal cancers,
melanomas
Potapova et al. (2000), Antonyak
et al. (2002), Tsuiki et al. (2003),
Yang et al. (2003), Xia et al. (2006),
Lopez-Bergami et al. (2007), Alex-
aki et al. (2008)
Ect2 Positive regulator of the Rho
GTPase pathway that controls
actin cytoskeleton functions
like cytokinesis
Ensures proper cytokinesis in
tumor cells
Glioblastoma, non-small cell
lung cancer
Salhia et al. (2008), Justilien et al.
(2011)
Skp2 F-box protein that functions as
part of SCFSkp2 to degrade
Cdk inhibitors p27Kip1 and
p21Cip1
Acts as an oncogene that
destroys tumor suppressor
proteins
Breast, prostate, liver and
pancreatic cancers,
melanomas, lymphomas
Lim et al. (2002), Radke et al.
(2005),Luetal.(2009),Roseetal.
(2011), Schuler et al. (2011)
Ube2C (UbcH10) Principal E2 enzyme the
APC/C collaborates with
Chromosome abnormalities
and mitotic slippage
Gastric carcinomas, cancers
of the lung, prostate, breast,
ovary, bladder, thyroid, uterus,
and esophagus
Okamoto et al. (2003), Pallante
et al. (2005), Berlingieri et al.
(2007), Jiang et al. (2008), van
Ree et al. (2010)
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via such a strategy is the proto-oncogene Skp2 (Fujita et al.,
2008, 2009). Downregulation of Skp2 by antisense RNA treat-
ment induces apoptosis in lung cancer cells (Yokoi et al., 2003).
Therefore, one possibility is utilizing compounds affecting Skp2
expression. For instance, treatment with EB1089 (vitamin D ana-
log) reduces Skp2 expression in treated cancer cells,thus promot-
ing increased stability of p27Kip1 protein and subsequent growth
arrest (Lin et al., 2003; Figure 3). Skp2 expression is also affected
by treatment with retinoic acid,thus altering the ability of p27Kip1
to be ubiquitinated (Nakamura et al., 2003). Furthermore, the
PPARgagonistTroglitazonereducesSkp2 mRNAlevels,leadingto
p27Kip1 accumulation (Koga et al.,2003).
Since the APC/C mediates Skp2 ubiquitination, enhancing
APC/C dependent degradation of Skp2 in cancer would also be
therapeutically attractive. One possible means of achieving this is
to inhibit casein kinase 1 (CK1), which controls APC/C depen-
dent degradation of Skp2 (Gao et al., 2009b,c). CK1 inhibition
induces Skp2 degradation since CK1 dependent phosphorylation
normally inhibits Skp2 nuclear translocation and interaction with
APC/CCdh1 (Gao et al.,2009b,c). An alternative strategy,however,
could be increasing the afﬁnity of Skp2 or other oncogenic sub-
stratesforAPC/C,thusreducingtheirproteinlevelsafterubiquiti-
nationanddegradation.Theadventofhigh-throughputscreensto
study APC/C-dependent degradation and protein–protein inter-
actions will facilitate identiﬁcation of small molecule agonists of
the APC/C–Skp2 interaction (Madoux et al., 2010; Zeng et al.,
2010).
AnotherpotentialAPC/CcancertargetisthesubstrateAurora-
A, since its overexpression is known to induce centrosome ampli-
ﬁcation and is overexpressed in human cancer cells (Zhou et al.,
1998). Recently, several compounds have been found to target
Aurora-A (Figure3). Curcumin,an active compound in turmeric
and curry that has been proven to induce tumor apoptosis and
inhibit tumor proliferation, invasion, angiogenesis, and metas-
tasis, has been shown to reduce Aurora-A mRNA expression in
human bladder cancer cells (Liu et al., 2011a). These curcumin-
induced phenomena were similar to those using Aurora-A small
interfering RNA and were attenuated by ectopic expression of
Aurora-A.Also,several cyclic peptide ligands inhibitingAurora-A
kinaseactivityhavebeendeveloped(Shominetal.,2011),although
future studies regarding proliferation of cancer cells still have to
be performed.
In addition to Aurora-A inhibition, there is pharmaceutical
interest in targeting Plk1 as Plk1 depletion in cancer cells dra-
matically inhibits cell proliferation and decreases viability (Liu
and Erikson, 2003; Xu et al., 2011; Yoon et al., 2011). Depletion
of Plk1 perturbs spindle assembly,which leads to activation of the
mitoticcheckpoint,prolongedmitoticarrest,andeventuallyapop-
tosis (Liu and Erikson, 2003). Thus, given the known functions
and effects of Plk1 inhibition, coupled with its wide overexpres-
sion pattern in cancer, a naturally occurring Plk1 inhibitor with
lowornotoxicitywillbeimmenselyusefulinpreventionaswellas
treatmentofcancer.NumerousPlk1inhibitorsareindevelopment
toevaluatetheirpotentialastreatmentsinoncology,someof them
inpreclinicalandclinicalphaseI/IIdevelopment(Schöffski,2009;
Figure 3). It will be interesting to determine whether enhancing
APC/C mediated degradation of Plk1 yield similar therapeutic
beneﬁts as Plk1 inhibitors currently in clinical trials.
TARGETING APC/CCdh1 ACTIVITY
Several lines of evidence suggest that modulation of the APC/C
complex is a good anti-cancer therapeutic strategy. Downregula-
tionofthecatalyticsubunitsApc2andApc11leadstogrowtharrest
and cell death in HeLa cells (Pray et al.,2002). Also,a small mole-
cule,tosyl-l-argininemethylester(TAME),whichbindstoAPC/C
and prevents its activation by Cdc20 and Cdh1, produces mitotic
arrest(Zengetal.,2010;Figure3).Furthermore,expressionofsev-
eral APC/C subunits is higher in tumor relative to normal tissue
(Wang et al., 2003). Collectively, these studies suggest that phar-
macological interference with APC/C activity through disruption
of protein–protein interaction is likely to have potent anti-tumor
activity (Pray et al.,2002; Huang et al.,2009).
Targeting upstream regulators of the APC/C complex control-
lingmitosisisalsoapromisingstrategy.Overexpressionof APC/C
inhibitorssuchasEmi1inmammaliancellsimpedescellcyclepro-
gression and results in cell death (Reimann et al., 2001). HDACs
FIGURE 3 | Cancer therapeutics related toAPC/C
Cdh1.Targeting the modulators, the APC/C
Cdh1 complex or its substrates could be a good anti-cancer strategy.
Some pharmacological treatments that regulate APC/C activity or substrate levels are currently in clinical trials or under development.
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might directly target APC/C to ensure proper chromosome
segregation and anti-tumor effects of HDAC inhibitors could be
attributed to this deregulation (Kimata et al., 2008). There are
emerging HDAC inhibitors that have been clinically validated as
therapeutic agents in cancer patients with hematologic malignan-
cies.TwoHDACinhibitors,vorinostat(pan-HDACinhibitor)and
depsipeptide(HDAC1andIIinhibitor)havebeenapprovedbythe
FDAandareunderfurtherclinicalinvestigation(Figure3).HDAC
inhibitors are well tolerated and clinically effective against hema-
tologic cancers (Duvic and Vu, 2007; Luu et al., 2008; Modesitt
et al.,2008).
CONCLUDING REMARKS
The APC/C is a unique ubiquitin ligase since it possesses a dis-
tinct structure and interacts with speciﬁc E2 enzymes required for
mediating substrate ubiquitination. Further, APC/CCdc20 activity
is essential in vitro and in vivo, suggesting that no other ubiquitin
ligasecansubstituteforAPC/C’sroleduringmitosis(Lietal.,2007;
Manchado et al., 2010). Similarly, APC/CCdh1 activity is required
for cell cycle traverse,differentiation,placental formation,and for
inhibiting tumorigenesis (Garcia-Higuera et al., 2008; Li et al.,
2008). These exciting studies suggest thatAPC/C plays a large role
in normal cell proliferation, which may be misregulated during
cancer.ConsistentwiththisnotionarenewstudieslinkingAPC/C
substrates and regulators to tumor formation. Thus, it may be
attractive to modulate APC/C substrate or regulator interaction
pharmacologically to ablate tumor growth, which would have the
advantage that speciﬁc interactions relevant to a cancer type can
be uniquely targeted.
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